Guselkumab for Hailey-Hailey disease
Treatments studied
Part of Genetic & congenital, Skin clinical trials.
This study tests the drug guselkumab to see if it can help control Hailey-Hailey disease, a rare skin condition. If you have moderate-to-severe HHD affecting multiple body areas, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Hailey-Hailey disease (with a skin biopsy)
- Your disease affects more than one body area and is at least moderately severe
- If you take other medications for the disease (like antibiotics or prednisone), you have been on a stable dose for at least 3 months and won't change in the next 6 months
- You are willing to have skin biopsies, blood draws, and full-body photos, and follow all study appointments
- You do not have a history of cancer (except minor skin cancers removed more than 6 months ago) or serious infections like HIV, hepatitis, or tuberculosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new topical gel called KB111 for treating Hailey-Hailey disease, a genetic skin condition that causes painful blisters. The study will check if the gel is safe and helps reduce symptoms.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This trial tests whether guselkumab, a newer biologic medication, can treat people who have both inflammatory bowel disease (Crohn's disease or ulcerative colitis) and spondyloarthritis (joint inflammation and pain). Researchers want to see if this one drug can help both conditions at the same time.
This trial looks at a type of immune cell (MAIT cells) in people with hidradenitis suppurativa (a skin condition causing painful bumps). It aims to understand how these cells work and how they relate to treatments like adalimumab, secukinumab, or bimekizumab. You may be able to join if you have moderate-to-severe HS and are about to start one of these treatments.
This study tests a drug called Guselkumab (already approved for other conditions) for treating moderate to severe ulcerative colitis. It aims to see how safe and effective the drug is in real-world patients who have not had success with other treatments.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
Hear when a new Hailey Hailey Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.